<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04465968</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG1807C</org_study_id>
    <nct_id>NCT04465968</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CRT, Durvalumab and Surgery for SST</brief_title>
  <acronym>DEEP_OCEAN</acronym>
  <official_title>Efficacy and Safety of Durvalumab Before and After Operation or Durvalumab as Maintenance Therapy After Chemoradiotherapy Against Superior Sulcus Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center Hospital East</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center Hospital East</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of multimodality treatment of pre- and post-operative durvalumab&#xD;
      therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor (SST) and&#xD;
      durvalumab maintenance therapy after chemoradiotherapy for unresectable SST&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of multimodality treatment of pre- and post-operative&#xD;
      durvalumab therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor&#xD;
      (SST) and durvalumab maintenance therapy after chemoradiotherapy for unresectable SST&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival rate (3y-OS)</measure>
    <time_frame>3 years</time_frame>
    <description>3-year overall survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year progression-free survival rate (3y-PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>3-year progression-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year progression-free survival rate (5y-PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>5-year progression-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival rate (5y-OS)</measure>
    <time_frame>5 years</time_frame>
    <description>5-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Mode of recurrence in surgical cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of local failure in surgical cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Objective response rate according to RECIST and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Proportion of surgical cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete resection rate (R0 rate)</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Proportion of pathologcal complete resection in surgical cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate (pCR rate)</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Proportion of pathologcal complete response in surgical cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathological response rate (MPR rate)</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Determination of major pathologic response rate is based on the method by Hellmann et al. on the pathological section. The percentage of residual tumor cells is calculated as viable tumor cells / tumor area × 100 (%). Tumor area includes viable tumor cells and interstitial tissue such as fibrosis, necrosis, and inflammatory cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Operation time in surgical cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Intraoperative blood loss in surgical cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>1 year 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of serious adverse events</measure>
    <time_frame>1 year 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of adverse events</measure>
    <time_frame>1 year 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Superior Sulcus Tumor</condition>
  <condition>Non-small Cell Lung Cancer Stage IIB</condition>
  <condition>Non Small Cell Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>CRT + Durvalumab ± Surgery + Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy)+2 courses of durvalumab followed by Surgery and adjuvant durvalumab for resectable SST or chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy) followed by maintenance durvalumab for unresectable SST.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 60 mg/m2, IV, day 1</description>
    <arm_group_label>CRT + Durvalumab ± Surgery + Durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1</intervention_name>
    <description>80 - 120 mg/day, PO, day 1-14</description>
    <arm_group_label>CRT + Durvalumab ± Surgery + Durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>concurrent radiotherapy</intervention_name>
    <description>66 Gy/33 Fr</description>
    <arm_group_label>CRT + Durvalumab ± Surgery + Durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.</description>
    <arm_group_label>CRT + Durvalumab ± Surgery + Durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.</description>
    <arm_group_label>CRT + Durvalumab ± Surgery + Durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.&#xD;
Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.&#xD;
Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1</description>
    <arm_group_label>CRT + Durvalumab ± Surgery + Durvalumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A definite diagnosis of non-small cell lung cancer has been obtained by biopsy from&#xD;
             the primary lesion.&#xD;
&#xD;
          2. Meet all of the following (UICC-TNM classification 8th edition). I. Regarding the&#xD;
             primary lesion, meet one of the following on chest CT. i. Direct invasion of the chest&#xD;
             wall at or above the height of the first rib (at least invasion of the parietal&#xD;
             pleura) ii. Direct invasion of the subclavian artery or vein II. Regarding regional&#xD;
             lymph nodes, meet either of the following by chest CT and FDG-PET/CT. Metastasis is&#xD;
             also considered if lymph node metastasis is determined by either chest CT or&#xD;
             FDG-PET/CT.&#xD;
&#xD;
             i. cN0 ii. cN1 and no metastases to #10, #11, and #12 lymph nodes iii. cN3&#xD;
             (ipsilateral supraclavicular lymph node metastasis) and no metastases in regional&#xD;
             lymph nodes (N1 and N2) other than &quot;#13, #14 lymph nodes&quot; III. No distant metastases&#xD;
             (including intrapulmonary metastases in the same ling lobe and in a different lung&#xD;
             lobe on the same side) on imaging tests including FDG-PET/CT&#xD;
&#xD;
          3. It is judged that radical resection is possible by lobectomy (including bilobectomy&#xD;
             for 2 lobes), which satisfies the following [1] and [2].&#xD;
&#xD;
             I. The board respiratory surgeon judges that none of the following is true based on&#xD;
             the image findings.&#xD;
&#xD;
             i. There is vertebral body infiltration that requires total spondylectomy ii. Presence&#xD;
             of spinal cord infiltration iii. Invaded trachea or tracheal bifurcation iv. Invasion&#xD;
             of aortic arch or ascending aorta v. Invading brachial plexus at C8 or higher vi.&#xD;
             Esophageal infiltration that requires esophageal reconstruction for resection vii.&#xD;
             Pneumonectomy is required for radical resection II. Meet all of the following. i.&#xD;
             Predicted postoperative forced expiratory volume of 1 second (FEV1.0) ≥ 800 mL within&#xD;
             56 days before registration ii. SpO2 &gt; 93% (room air) with the latest inspection value&#xD;
             within 14 days before registration&#xD;
&#xD;
          4. Consult with the radiotherapy doctor and it is judged that all of the following are&#xD;
             met.&#xD;
&#xD;
             I. Radiation therapy is possible according to the protocol II. The irradiation field&#xD;
             does not reach the hilum&#xD;
&#xD;
          5. The age of the registration date is 20 years or older and 75 years or yonger.&#xD;
&#xD;
          6. Performance status (PS) is 0 or 1 according to ECOG standards (PS must be described in&#xD;
             medical records)&#xD;
&#xD;
          7. The presence or absence of measurable lesions is not required.&#xD;
&#xD;
          8. No history of following surgery irrespective of whether for a benign or malignant&#xD;
             lesion.&#xD;
&#xD;
             I. Thoracoscopic surgery or thoracotomy with excision of the affected lung or&#xD;
             esophagus or mediastinum (however, a history of thoracoscopic surgery without wedge&#xD;
             resection or lung, esophagus, or mediastinal resection (eg, pleural biopsy)) is&#xD;
             allowed) II. Median sternotomy surgery (with or without organ resection) III.&#xD;
             Pulmonary resection other than wedge resection of the contralateral lung (whether&#xD;
             open-heart surgery or thoracoscopic surgery)&#xD;
&#xD;
          9. There is no history of chemotherapy, including treatment for other cancer types&#xD;
             (including molecular targeted therapies and immune checkpoint inhibitors). However,&#xD;
             the history of drug therapy as adjuvant therapy is allowed if it was completed more&#xD;
             than 3 years ago. In addition, a history of hormone therapy for other cancer types is&#xD;
             allowed.&#xD;
&#xD;
         10. If there is a history of radiotherapy including other cancer types, the lung, hilum,&#xD;
             mediastinum, and supraclavicular fossa are not included in the irradiation field.&#xD;
&#xD;
         11. Chest CT does not show interstitial pneumonia or pulmonary fibrosis.&#xD;
&#xD;
         12. No history of complication of autoimmune disease or chronic or recurrent autoimmune&#xD;
             disease. However, patients with type 1 diabetes which is well controlled by&#xD;
             appropriate treatment, hyperthyroidism/hypothyroidism that requires only antithyroid&#xD;
             drug/hormone replacement therapy, autoimmune skin disease that does not require&#xD;
             systemic treatment (Pemphigus, psoriasis vulgaris, pemphigus vulgaris, vitiligo), and&#xD;
             celiac disease controlled only by dietary control are regarded as eligible if they&#xD;
             have been inactive in the past 5 years, even with a history of autoimmune&#xD;
             complications or history.&#xD;
&#xD;
         13. No surgical treatment with general anesthesia within 14 days (2 weeks) before&#xD;
             registration.&#xD;
&#xD;
         14. No systemic administration of steroids, other immunosuppressive drugs, or&#xD;
             immunoglobulins within 28 days (4 weeks) before registration. However, those that meet&#xD;
             the following conditions are allowed.&#xD;
&#xD;
             I. Intranasal/inhalation/topical steroid injection or local steroid injection (for&#xD;
             example, intra-articular injection) II. Systemic administration of steroid drugs at a&#xD;
             dose of 10 mg/day or less in terms of prednisolone III. Steroids as premedication (eg&#xD;
             CT premedication)&#xD;
&#xD;
         15. Can be taken orally.&#xD;
&#xD;
         16. No ischemic changes were observed on the latest 12-lead ECG within 28 days before&#xD;
             registration. However, if a 12-lead electrocardiogram shows ischemic changes,&#xD;
             echocardiography, exercise electrocardiography, etc. should be performed, and if it is&#xD;
             judged that new treatment for ischemic heart disease is not necessary, it is&#xD;
             qualified.&#xD;
&#xD;
         17. The latest inspection value within 14 days before registration (possible on the same&#xD;
             day two weeks before the registration date) satisfies all of the following.&#xD;
&#xD;
             I. White blood cell count ≧4,000/mm3 II. Hemoglobin ≥ 11.0 g/dL (no blood transfusion&#xD;
             within 14 days before the blood sampling date of the test used for registration) III.&#xD;
             Platelet count ≧10×104 /mm3 IV. Total bilirubin ≤ 2.0 mg/dL V. AST ≤ 75 U/L VI. ALT ≤&#xD;
             75 U/L VII. Serum creatinine ≤ 1.2 mg/dL&#xD;
&#xD;
         18. Written informed consent from the patient to participate in the study.&#xD;
&#xD;
         19. The attending physician can judge that the enrolled patients understand the treatment&#xD;
             and evaluation schedule of this study and can comply with them.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having active double cancer (simultaneous double cancer/multiple cancer and&#xD;
             metachronous double cancer/multiple cancer with a disease-free period of 3 years or&#xD;
             less, even if the disease-free period is less than 3 years, clinical The 5-year&#xD;
             relative survival rate is similar to that of stage I prostate cancer, clinical stage 0&#xD;
             completely responded to radiation therapy, stage I laryngeal cancer, and complete&#xD;
             excision of the following pathological stage cancers. History of cancer equivalent to&#xD;
             95% or more is not included in active double cancer/multiple cancer). Gastric cancer&#xD;
             &quot;adenocarcinoma (general type)&quot;: Stage 0-I, colon cancer (adenocarcinoma): Stage 0-I,&#xD;
             rectal cancer (adenocarcinoma): Stage 0-I, esophageal cancer (squamous cell carcinoma,&#xD;
             glandular) Squamous cell carcinoma, basal cell carcinoma): Stage 0, breast cancer&#xD;
             (non-invasive ductal carcinoma, lobular carcinoma): Stage 0, breast cancer (invasive&#xD;
             ductal carcinoma, lobular invasive carcinoma, Paget's disease): 0 Stage-IIA,&#xD;
             endometrial cancer (endometrioid adenocarcinoma, mucinous adenocarcinoma): Stage I,&#xD;
             prostate cancer (adenocarcinoma): Stage I-II, cervical cancer (squamous cell&#xD;
             carcinoma): Stage 0, thyroid cancer (Papillary cancer, follicular cancer): stage I,&#xD;
             stage II, stage III, renal cancer (clear cell carcinoma, chromophobe cell carcinoma):&#xD;
             stage I, non-melanoma skin cancer, malignant melanoma without a definite diagnosis,&#xD;
             etc. Lesions of intramucosal cancer&#xD;
&#xD;
          2. Has an infectious disease that requires systemic treatment (including active pulmonary&#xD;
             tuberculosis).&#xD;
&#xD;
          3. When registering, a fever of 38.0°C or higher is generated.&#xD;
&#xD;
          4. Women who are pregnant, possibly pregnant, within 28 days of delivery, or&#xD;
             breastfeeding. A man who wants a partner to become pregnant. Or a reproductive male or&#xD;
             female patient who is not willing to use an effective contraceptive by Week 13 (Day&#xD;
             91) after the last dose of durvalumab (see 6.4.7.).&#xD;
&#xD;
          5. Participation in the study is considered to be difficult due to the combination of&#xD;
             mental illnesses or symptoms that impair daily life.&#xD;
&#xD;
          6. Continuous systemic administration (oral or intravenous) of steroid drugs or other&#xD;
             immunosuppressive drugs in excess of 10 mg/day in terms of prednisolone.&#xD;
&#xD;
          7. With uncontrolled diabetes.&#xD;
&#xD;
          8. With uncontrolled hypertension.&#xD;
&#xD;
          9. A gastrointestinal disorder accompanied by uncontrolled diarrhea.&#xD;
&#xD;
         10. With unstable angina (angina with onset or exacerbation of attack within the last 3&#xD;
             weeks) or a history of myocardial infarction within 6 months.&#xD;
&#xD;
         11. Poor valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy,&#xD;
             congestive heart failure, and arrhythmia.&#xD;
&#xD;
         12. Chest CT reveals severe emphysema.&#xD;
&#xD;
         13. Either HBs antigen, HCV antibody, or HIV1/2 antibody is positive.&#xD;
&#xD;
         14. Continuous use of flucytosine (Ancotil®) is required.&#xD;
&#xD;
         15. Participating in another clinical trial (excluding observational studies) during the 6&#xD;
             months prior to enrollment.&#xD;
&#xD;
         16. A history of allogeneic organ transplant.&#xD;
&#xD;
         17. A history of active primary immunodeficiency.&#xD;
&#xD;
         18. Live vaccines (BCG, polio, measles-rubella mixture, measles, rubella, mumps,&#xD;
             chickenpox, yellow fever, rotavirus, etc.) have been administered within 30 days&#xD;
             before registration.&#xD;
&#xD;
         19. Has hypersensitivity or allergy to the test drug or its additives used in this test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Masahiro Tsuboi, MD</last_name>
    <phone>+81-4-7133-1111</phone>
    <phone_ext>91373</phone_ext>
    <email>mtsuboi@east.ncc.go.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keiju Aokage, MD</last_name>
    <phone>+81-4-7133-1111</phone>
    <phone_ext>91483</phone_ext>
    <email>kaokage@east.ncc.go.jp</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center Hospital East</investigator_affiliation>
    <investigator_full_name>Masahiro Tsuboi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Superior Sulcus Tumor</keyword>
  <keyword>Pancoast Tumor</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Multi-modality therapy</keyword>
  <keyword>Neoadjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04465968
org study id: JCOG1807C
nct id: NCT04465968
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The safety and efficacy of multimodality treatment of pre- and post-operative durvalumab
      therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor (SST) and
      durvalumab maintenance therapy after chemoradiotherapy for unresectable SST
To evaluate the safety and efficacy of multimodality treatment of pre- and post-operative
      durvalumab therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor
      (SST) and durvalumab maintenance therapy after chemoradiotherapy for unresectable SST
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: 3-year overall survival rate (3y-OS)
time frame: 3 years
description: 3-year overall survival rate
measure: 3-year progression-free survival rate (3y-PFS)
time frame: 3 years
description: 3-year progression-free survival rate
measure: 5-year progression-free survival rate (5y-PFS)
time frame: 5 years
description: 5-year progression-free survival rate
measure: 5-year overall survival rate (5y-OS)
time frame: 5 years
description: 5-year overall survival rate
measure: Mode of recurrence
time frame: 5 years
description: Mode of recurrence in surgical cases
measure: Local recurrence rate
time frame: 5 years
description: Proportion of local failure in surgical cases
measure: Objective response rate (ORR)
time frame: 1 year 6 months
description: Objective response rate according to RECIST and iRECIST
measure: Resection rate
time frame: 1 year 6 months
description: Proportion of surgical cases
measure: Pathological complete resection rate (R0 rate)
time frame: 1 year 6 months
description: Proportion of pathologcal complete resection in surgical cases
measure: Pathological complete response rate (pCR rate)
time frame: 1 year 6 months
description: Proportion of pathologcal complete response in surgical cases
measure: Major pathological response rate (MPR rate)
time frame: 1 year 6 months
description: Determination of major pathologic response rate is based on the method by Hellmann et al. on the pathological section. The percentage of residual tumor cells is calculated as viable tumor cells / tumor area × 100 (%). Tumor area includes viable tumor cells and interstitial tissue such as fibrosis, necrosis, and inflammatory cells.
measure: Operation time
time frame: 1 year 6 months
description: Operation time in surgical cases
measure: Blood loss
time frame: 1 year 6 months
description: Intraoperative blood loss in surgical cases
measure: Adverse event rate
time frame: 1 year 6 months
measure: Incidences of serious adverse events
time frame: 1 year 6 months
measure: Incidences of adverse events
time frame: 1 year 6 months
arm group label: CRT + Durvalumab ± Surgery + Durvalumab
arm group type: Experimental
description: Concurrent chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy)+2 courses of durvalumab followed by Surgery and adjuvant durvalumab for resectable SST or chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy) followed by maintenance durvalumab for unresectable SST.
intervention type: Drug
intervention name: Cisplatin
description: Cisplatin 60 mg/m2, IV, day 1
arm group label: CRT + Durvalumab ± Surgery + Durvalumab
intervention type: Drug
intervention name: S1
description: 80 - 120 mg/day, PO, day 1-14
arm group label: CRT + Durvalumab ± Surgery + Durvalumab
intervention type: Radiation
intervention name: concurrent radiotherapy
description: 66 Gy/33 Fr
arm group label: CRT + Durvalumab ± Surgery + Durvalumab
intervention type: Drug
intervention name: Durvalumab
description: preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
arm group label: CRT + Durvalumab ± Surgery + Durvalumab
intervention type: Procedure
intervention name: Surgery
description: Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
arm group label: CRT + Durvalumab ± Surgery + Durvalumab
intervention type: Drug
intervention name: Durvalumab
description: (For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.
Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.
Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1
arm group label: CRT + Durvalumab ± Surgery + Durvalumab
criteria: 
gender: All
minimum age: 20 Years
maximum age: 75 Years
healthy volunteers: No
last name: Masahiro Tsuboi, MD
phone: +81-4-7133-1111
phone ext: 91373
email: mtsuboi@east.ncc.go.jp
last name: Keiju Aokage, MD
phone: +81-4-7133-1111
phone ext: 91483
email: kaokage@east.ncc.go.jp
responsible party type: Principal Investigator
investigator affiliation: National Cancer Center Hospital East
investigator full name: Masahiro Tsuboi
investigator title: MD
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Durvalumab
mesh term: Antibodies, Monoclonal
sharing ipd: No